These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 21303472)
1. Rituximab and lupus interstitial lung disease: friend or foe? Efthimiou P; Kukar M; Hersh A Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472 [No Abstract] [Full Text] [Related]
2. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab. Nikiphorou E; Hall FC Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401 [No Abstract] [Full Text] [Related]
10. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab. Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008 [No Abstract] [Full Text] [Related]
11. Targetoid-like Lesions in the Setting of Systemic Lupus Erythematosus: A Case of Rowell Syndrome. Ward JM; Hess JN; Davis LS J Rheumatol; 2020 Feb; 47(2):298-299. PubMed ID: 32007943 [No Abstract] [Full Text] [Related]
12. [Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report]. Mrabet D; Meddeb N; Sahli H; Saadi F; Chéour E; Elleuch M; Sellami S Therapie; 2010; 65(6):581-3. PubMed ID: 23189757 [No Abstract] [Full Text] [Related]
14. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Marie I; Dominique S; Janvresse A; Levesque H; Menard JF Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877 [TBL] [Abstract][Full Text] [Related]
15. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome. Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469 [No Abstract] [Full Text] [Related]
16. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J; Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449 [TBL] [Abstract][Full Text] [Related]
17. Autoimmune haemolytic anaemia as an initial presentation of primary Sjögren syndrome. Subbarayudu B; Sharma MS; Sreemannarayana P Intern Med J; 2014 Dec; 44(12a):1259-61. PubMed ID: 25442764 [No Abstract] [Full Text] [Related]
18. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X; Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531 [TBL] [Abstract][Full Text] [Related]
19. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214 [No Abstract] [Full Text] [Related]
20. [Rituximab therapy for severe pediatric systemic lupus erythematosus]. Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]